Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy - PubMed (original) (raw)
Clinical Trial
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy
K J Ruhnau et al. Diabet Med. 1999 Dec.
Abstract
Aims: To evaluate the efficacy and safety of short-term oral treatment with the antioxidant thioctic acid (TA) on neuropathic symptoms and deficits in patients with Type 2 diabetes mellitus with symptomatic polyneuropathy.
Methods: Patients were randomly assigned to oral treatment with 600 mg of TA t.i.d. (n = 12) or placebo (n = 12) for 3 weeks. Neuropathic symptoms (pain, burning, paraesthesiae, and numbness) in the feet were scored at weekly intervals and summarized as a Total Symptom Score (TSS). The Hamburg Pain Adjective List (HPAL) and the Neuropathy Disability Score (NDS) were assessed at baseline and day 19.
Results: At baseline the TSS, HPAL, and NDS were not significantly different between the groups. The TSS in the foot decreased from baseline to day 19 by -3.75 +/- 1.88 points (-47%) in the TA group and by -1.94 +/- 1.50 points (-24%) in the placebo group (P= 0.021 for TA vs. placebo). The total HPAL score decreased from baseline to day 19 by -2.20 +/- 1.65 points (-60%) in the TA group and by -0.96 +/- 1.32 points (-29%) in the placebo group (P = 0.072 for TA vs. placebo). The NDS decreased by -0.27 +/- 0.47 points in the TA group, whereas it slightly increased by +0.18 +/- 0.4 points in the placebo group (P = 0.025 for TA vs. placebo). No differences between the groups were noted regarding the rates of adverse events.
Conclusions: These preliminary findings indicate that oral treatment with 600 mg of TA t.i.d. for 3 weeks may improve symptoms and deficits resulting from polyneuropathy in Type 2 diabetic patients, without causing significant adverse reactions.
Similar articles
- Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R. Ziegler D, et al. Diabetes Care. 1999 Aug;22(8):1296-301. doi: 10.2337/diacare.22.8.1296. Diabetes Care. 1999. PMID: 10480774 Clinical Trial. - Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA. Ziegler D, et al. Diabetologia. 1995 Dec;38(12):1425-33. doi: 10.1007/BF00400603. Diabetologia. 1995. PMID: 8786016 Clinical Trial. - Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Ziegler D, et al. Diabet Med. 2004 Feb;21(2):114-21. doi: 10.1111/j.1464-5491.2004.01109.x. Diabet Med. 2004. PMID: 14984445 - Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy.
Ziegler D, Gries FA. Ziegler D, et al. Diabetes. 1997 Sep;46 Suppl 2:S62-6. doi: 10.2337/diab.46.2.s62. Diabetes. 1997. PMID: 9285502 Review. - Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review.
Ziegler D. Ziegler D. Treat Endocrinol. 2004;3(3):173-89. doi: 10.2165/00024677-200403030-00005. Treat Endocrinol. 2004. PMID: 16026113 Review.
Cited by
- Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Hsieh RY, Huang IC, Chen C, Sung JY. Hsieh RY, et al. Nutrients. 2023 Aug 18;15(16):3634. doi: 10.3390/nu15163634. Nutrients. 2023. PMID: 37630823 Free PMC article. Review. - Peripheral Neuropathies Derived from COVID-19: New Perspectives for Treatment.
Córdova-Martínez A, Caballero-García A, Pérez-Valdecantos D, Roche E, Noriega-González DC. Córdova-Martínez A, et al. Biomedicines. 2022 May 2;10(5):1051. doi: 10.3390/biomedicines10051051. Biomedicines. 2022. PMID: 35625788 Free PMC article. Review. - The Role of Biofactors in Diabetic Microvascular Complications.
Ziegler D, Porta M, Papanas N, Mota M, Jermendy G, Beltramo E, Mazzeo A, Caccioppo A, Striglia E, Serhiyenko V, Serhiyenko A, Rosta L, Stirban OA, Putz Z, Istenes I, Horváth V, Kempler P. Ziegler D, et al. Curr Diabetes Rev. 2022;18(4):e250821195830. doi: 10.2174/1871527320666210825112240. Curr Diabetes Rev. 2022. PMID: 34433401 Free PMC article. - Alpha-Lipoic Acid as a Nutritive Supplement for Humans and Animals: An Overview of Its Use in Dog Food.
Anthony RM, MacLeay JM, Gross KL. Anthony RM, et al. Animals (Basel). 2021 May 19;11(5):1454. doi: 10.3390/ani11051454. Animals (Basel). 2021. PMID: 34069383 Free PMC article. Review. - Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review).
Bondar A, Popa AR, Papanas N, Popoviciu M, Vesa CM, Sabau M, Daina C, Stoica RA, Katsiki N, Stoian AP. Bondar A, et al. Exp Ther Med. 2021 Jul;22(1):690. doi: 10.3892/etm.2021.10122. Epub 2021 Apr 29. Exp Ther Med. 2021. PMID: 33986855 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical